Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
Relmada Therapeutics, Inc. on 6ix
In the deck
Story so far
Earlier from Relmada Therapeutics
- Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
- Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
- Relmada Therapeutics Announces Proposed Public Offering of Common Stock
- Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Later from Relmada Therapeutics
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
- Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
- Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
- Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Follow Relmada Therapeutics into a list and get an email when it puts out news.
Follow Relmada Therapeutics